Bridgebio Pharma Stock Buy Hold or Sell Recommendation
| BBIO Stock | USD 54.26 0.45 0.84% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BridgeBio Pharma is 'Cautious Hold'. The recommendation algorithm takes into account all of BridgeBio Pharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out BridgeBio Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide. In addition, we conduct extensive research on individual companies such as BridgeBio and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
BridgeBio | Build AI portfolio with BridgeBio Stock |
Execute BridgeBio Pharma Buy or Sell Advice
The BridgeBio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BridgeBio Pharma. Macroaxis does not own or have any residual interests in BridgeBio Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BridgeBio Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Fair | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BridgeBio Pharma Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 226.84 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2IR9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week |
BridgeBio Pharma Returns Distribution Density
The distribution of BridgeBio Pharma's historical returns is an attempt to chart the uncertainty of BridgeBio Pharma's future price movements. The chart of the probability distribution of BridgeBio Pharma daily returns describes the distribution of returns around its average expected value. We use BridgeBio Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BridgeBio Pharma returns is essential to provide solid investment advice for BridgeBio Pharma.
| Mean Return | 0.29 | Value At Risk | -3.4 | Potential Upside | 3.68 | Standard Deviation | 2.48 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BridgeBio Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BridgeBio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as BridgeBio Pharma, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading BridgeBio Pharma back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2025-06-30 | 2.8 M | Goldman Sachs Group Inc | 2025-06-30 | 2.6 M | Alliancebernstein L.p. | 2025-06-30 | 2.5 M | Laurion Capital Management Lp | 2025-06-30 | 2.4 M | Two Sigma Investments Llc | 2025-06-30 | 2.3 M | Macquarie Group Ltd | 2025-06-30 | 2.1 M | D. E. Shaw & Co Lp | 2025-06-30 | 2.1 M | Fmr Inc | 2025-06-30 | 2 M | Norges Bank | 2025-06-30 | 2 M | Viking Global Investors Lp | 2025-06-30 | 18.6 M | Vanguard Group Inc | 2025-06-30 | 16.5 M |
BridgeBio Pharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (38.7M) | (166.2M) | 453.1M | 54.0M | 60.8M | 63.8M | |
| Change In Cash | (5.5M) | 37.7M | 20.5M | (22.2M) | 288.5M | 302.9M | |
| Net Borrowings | 36.9M | 537.0M | 1.1B | (20.5M) | (23.6M) | (22.4M) | |
| Free Cash Flow | (407.2M) | (546.2M) | (425.8M) | (529.0M) | (521.7M) | (547.7M) | |
| Other Non Cash Items | 31.2M | 18.5M | (61.3M) | 103.9M | (79.3M) | (75.3M) | |
| Dividends Paid | 0.0 | 997K | 537.0M | 3.8M | 4.4M | 4.2M | |
| Capital Expenditures | 7.5M | 48.2M | 6.3M | 1.3M | 933K | 886.4K | |
| Net Income | (505.5M) | (586.5M) | (484.7M) | (643.2M) | (543.3M) | (570.5M) | |
| End Period Cash Flow | 358.7M | 396.4M | 416.9M | 394.7M | 683.2M | 432.1M | |
| Change To Netincome | 17.9M | 62.5M | 111.1M | 112.7M | 129.6M | 136.1M | |
| Change To Inventory | (2.8M) | 19.7M | (15.2M) | (15.3M) | (13.8M) | (13.1M) |
BridgeBio Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BridgeBio Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BridgeBio Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BridgeBio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.26 | |
β | Beta against Dow Jones | 0.30 | |
σ | Overall volatility | 2.49 | |
Ir | Information ratio | 0.08 |
BridgeBio Pharma Volatility Alert
BridgeBio Pharma currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.26. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BridgeBio Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BridgeBio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.BridgeBio Pharma Fundamentals Vs Peers
Comparing BridgeBio Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BridgeBio Pharma's direct or indirect competition across all of the common fundamentals between BridgeBio Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as BridgeBio Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BridgeBio Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing BridgeBio Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BridgeBio Pharma to competition |
| Fundamentals | BridgeBio Pharma | Peer Average |
| Return On Equity | -17.9 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Operating Margin | (1.21) % | (5.51) % |
| Current Valuation | 11.29 B | 16.62 B |
| Shares Outstanding | 191.17 M | 571.82 M |
| Shares Owned By Insiders | 4.76 % | 10.09 % |
| Shares Owned By Institutions | 95.24 % | 39.21 % |
| Number Of Shares Shorted | 17.35 M | 4.71 M |
| Price To Earning | (13.72) X | 28.72 X |
| Price To Book | 123.68 X | 9.51 X |
| Price To Sales | 43.99 X | 11.42 X |
| Revenue | 221.9 M | 9.43 B |
| Gross Profit | 226.84 M | 27.38 B |
| EBITDA | (436.83 M) | 3.9 B |
| Net Income | (543.35 M) | 570.98 M |
| Cash And Equivalents | 715.71 M | 2.7 B |
| Cash Per Share | 4.83 X | 5.01 X |
| Total Debt | 1.73 B | 5.32 B |
| Debt To Equity | 4.61 % | 48.70 % |
| Current Ratio | 5.46 X | 2.16 X |
| Book Value Per Share | (9.35) X | 1.93 K |
| Cash Flow From Operations | (520.73 M) | 971.22 M |
| Short Ratio | 7.96 X | 4.00 X |
| Earnings Per Share | (4.13) X | 3.12 X |
| Price To Earnings To Growth | 0.05 X | 4.89 X |
| Target Price | 66.47 | |
| Number Of Employees | 725 | 18.84 K |
| Beta | 1.36 | -0.15 |
| Market Capitalization | 10.37 B | 19.03 B |
| Total Asset | 919.34 M | 29.47 B |
| Retained Earnings | (3.1 B) | 9.33 B |
| Working Capital | 566.29 M | 1.48 B |
| Current Asset | 513.67 M | 9.34 B |
Note: Disposition of 5442 shares by Neil Kumar of BridgeBio Pharma at 51.8535 subject to Rule 16b-3 [view details]
BridgeBio Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BridgeBio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BridgeBio Pharma Buy or Sell Advice
When is the right time to buy or sell BridgeBio Pharma? Buying financial instruments such as BridgeBio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BridgeBio Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Toys Thematic Idea Now
Toys
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BridgeBio Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.13) | Revenue Per Share | Quarterly Revenue Growth 49.999 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.